Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 17, 2024, serves as a transaction notification for the month of April 2024. The document discloses share transactions executed by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. These transactions occurred on April 16, 2024, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain company-wide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share acquisition details:
- Transaction Type: Increase in notional interest or acquisition of shares via dividend re-investment.
- Underlying Event: Re-investment of dividends paid to shareholders on April 11, 2024.
- Plans Involved: Deferred Annual Bonus Plan and Performance Share Plan.
- Share Prices: Ordinary Shares traded at £16.2900; American Depositary Shares (ADSs) traded at $40.8000.
Material Changes
The filing does not report material changes to the company's financial position or operations. It details routine, non-discretionary increases in shareholdings for 14 senior executives resulting from dividend re-investment plans. No sales of shares or changes in beneficial ownership outside of these plan mechanics were reported.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or risk factors. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the dividend payment date of April 11, 2024, to confirm the timing of the re-investment.
- Confirm the share prices of £16.2900 (Ordinary Shares) and $40.8000 (ADSs) against market data for April 16, 2024.
- Review the specific holding periods mentioned, such as the 2-year holding period for the Performance Share Plan.
- Check the total volume of shares acquired by each executive to assess their total exposure relative to their compensation plans.